Today we dive into two rare but life-disrupting sleep disorders: narcolepsy and idiopathic hypersomnia. People with these conditions don’t just feel tired — they can fall asleep suddenly while driving, talking, or working, or sleep 11+ hours and still feel completely unrefreshed with intense brain fog and sleep drunkenness. Our guest is world-renowned sleep expert Dr. Logan Schneider, board-certified neurologist and sleep medicine specialist, Adjunct Clinical Associate Professor at Stanford University, and Clinical Lead for Sleep Health at Google. We cover causes (including the loss of the brain chemical orexin/hypocretin), symptoms like cataplexy, diagnosis, the only FDA-approved medication for idiopathic hypersomnia (Xywav), made by Jazz Pharmaceuticals @JazzPharma, lifestyle strategies, common myths, and how to find the right specialist. Timestamps: 0:00 – Introduction & episode overview 1:07 – Meet Dr. Logan Schneider 2:06 – What are sleep disorders and why they matter 3:12 – How common is excessive daytime sleepiness? 5:28 – What is narcolepsy and its main symptoms 6:55 – Sleep attacks and the danger of falling asleep while driving 8:04 – Type 1 narcolepsy: the orexin/hypocretin deficiency 10:25 – Is it autoimmune? What triggers it? 10:29 – How is narcolepsy diagnosed? 12:10 – Narcolepsy Type 2 explained 13:42 – What is cataplexy and REM sleep? 15:07 – Who gets narcolepsy (age & gender) 16:55 – Idiopathic hypersomnia: how it differs from narcolepsy 18:24 – Sleeping 9–11 hours and still exhausted 19:24 – Brain fog and “sleep drunkenness” 21:06 – Does coffee help these disorders? 22:39 – Xywav (low-sodium oxybate): how it works for both conditions 26:32 – Why the low-sodium version matters for heart health 28:56 – REMS program and why it’s a controlled substance 31:45 – Who is a candidate for Xywav? 35:33 – Lifestyle tips and support strategies 37:02 – Common misconceptions about these disorders 40:08 – Do you need a sleep study before treatment? 42:10 – Who can prescribe Xywav? 44:14 – How to find a sleep specialist near you 45:50 – Final message: “Sleepiness is red alert” Subscribe for more expert medical interviews! #Narcolepsy #IdiopathicHypersomnia #SleepDisorders #ExcessiveDaytimeSleepiness #Cataplexy #Xywav #SleepMedicine #BrainFog #Hypersomnia #NarcolepsyAwareness #SleepHealth #DoctorPodcasts #Cykiert #sleep

CRISPR gene editing is no longer science fiction — it’s an FDA-approved treatment transforming lives with sickle cell disease and beta-thalassemia. In this episode of the DoctorPodcasts, host Dr. Robert Cykiert sits down with Dr. Akshay Sharma, Associate Member at St. Jude Children’s Research Hospital and a leading expert in gene therapy and bone marrow transplantation. Dr. Sharma was involved in the clinical trials that led to the approval of Casgevy. Discover how a single DNA edit can raise fetal hemoglobin, stop painful crises, and potentially free patients from lifelong transfusions and organ damage. Learn the real differences between gene therapy and traditional bone marrow transplant, the full treatment timeline, risks (including busulfan chemotherapy), expansion to younger patients, and how AI could accelerate the next generation of cures. This is one of the most important medical breakthroughs of our time. Timeline / Chapters: 0:00 – Introduction & Guest Welcome 2:16 – What is Sickle Cell Disease? The Genetic Defect Explained 5:37 – Inheritance Pattern & How Many People Are Affected 7:04 – Sickle Cell Trait vs. Disease 7:50 – Historical Treatments: Supportive Care, Hydroxyurea & More 12:23 – Bone Marrow Transplant History (First Success at St. Jude in 1983) 13:27 – What is Beta-Thalassemia? 15:40 – How Casgevy Differs from Transfusions & Transplants 20:25 – How CRISPR Gene Editing Works (The Molecular Scissors) 25:48 – Clinical Trials, FDA Approval (Dec 2023) & Age Expansion 30:36 – Treating Young Children: Long-Term Outlook 34:54 – Full Treatment Timeline (9–12 Months) 37:12 – Role of AI in Future Gene Therapies 39:35 – Closing Thoughts #Casgevy, #CRISPR, #sickle #thalassemia, #gene #hemoglobin, #bonemarrowtransplant, , , , #Vertex #CRISPR #DNA #Doctorpodcasts #Cykiert Subscribe for more expert interviews on breakthrough medical treatments. Like, share, and comment with your questions!

🎬Welcome to Episode 157 of the DoctorPodcasts Show! In this episode, host Dr. Robert Cykiert interviews board-certified ophthalmologist and oculoplastic surgeon Dr. Amy Patel Jain, M.D. to discuss a condition affecting thousands of people every day: Thyroid Eye Disease (TED). As a co-investigator in pivotal clinical trials, Dr. Patel Jain shares her deep expertise on how TED impacts patients' eyes and quality of life. We dive into traditional surgical treatments like orbital decompression, the paradigm shift brought on by #Tepezza, and breaking news regarding the June 2026 FDA approval of a brand-new five-infusion targeted biologic treatment: #Lumvoa.If you or a loved one are navigating the challenges of this autoimmune condition, this deep-dive interview offers the clinical insights and treatment options you need to know.

Don't forget to SUBSCRIBE, FOLLOW, LIKE, and REPOST to help us spread awareness!⏳ Video Timeline (Chapters)

0:00 — Introduction to Episode 157 & Guest Dr. Amy Patel Jain

2:02 — What is Thyroid Eye Disease (TED) and How Does it Affect the Eyes?

3:26 — TED vs. Graves' Disease: Can You Have TED Without an Active Thyroid Problem?

4:21 — What Causes TED? The Role of TSH and IGF-1R Receptors5:08 — Who is at Risk? Demographics, Genetics, and the Impact of Smoking

7:10 — How Many People in the USA Are Affected by TED?

7:24 — Types of TED: Acute vs. Chronic and Active vs. Inactive Inflammation

10:05 — How TED Affects Patient Quality of Life, Mental Health, and Daily Functioning

11:19 — Traditional TED Treatments: Steroids, Radiation, and Multi-Stage Surgery

13:25 — How Orbital Decompression Surgery Works (The "Ice Cream Cone" Analogy)

15:25 — The Impact of Tepezza: A Paradigm Shift in Medical Treatment

16:24 — Breaking News: How the New Drug Lumvoa Works (Mechanism of Action)

17:33 — Lumvoa vs. Tepezza: Comparing Infusion Times, Frequency, and Treatment Burden

18:35 — Clinical Results: How Quickly Do Patients See Results with Lumvoa?

19:13 — Why TED Causes Diplopia (Double Vision) & Asymmetric Muscle Expansion

20:39 — Main Side Effects and Clinical Considerations (Hypoglycemia, Hearing Changes, IBD)

22:19 — Who is the Ideal Candidate for Lumvoa & Navigating the Viridian Cares Program

24:18 — Will Biologics Reduce the Need for Severe Orbital Decompression Surgeries?

25:42 — Outro & Closing Remarks

🏷️ #ThyroidEyeDisease #TED #Lumvoa #Tepezza #GravesDisease #BulgingEyes #Ophthalmology #AutoimmuneDisease #DoubleVision #ThyroidAwareness #DoctorPodcastsShow #proptosis #exophthalmos Medical Disclaimer: This video is for informational and educational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Can a simple blood test catch cancer recurrence months — or even years — before a scan would ever show it? Dr. Alan Tan, a board-certified medical oncologist and leading expert in genitourinary (GU) cancers — kidney, bladder, and prostate cancer — as well as melanoma, joins Dr. Robert Cykiert to break down Minimal Residual Disease (MRD) and circulating tumor DNA (ctDNA) testing: what it is, how it works, and why it's changing how cancer is monitored and treated.Dr. Tan serves as Vice President of MRD Research and Clinical Strategy at Tempus AI, and is Associate Professor of Medicine and GU Oncology Lead at Vanderbilt University Medical Center / Vanderbilt-Ingram Cancer Center in Nashville. He shares his hands-on clinical experience using the Personalis NeXT Personal test — including how it's helping detect recurrence at ultra-sensitive levels, guide treatment decisions, and potentially reduce unnecessary chemotherapy and immunotherapy toxicity for patients who are already cured.🔑 TOPICS COVERED:00:00 – Catching recurrence before scans show it00:38 – Welcome & episode introduction01:51 – Meet Dr. Alan Tan03:38 – What is MRD? What is ctDNA?06:19 – Why a "clear scan" doesn't mean cancer-free08:19 – How the blood test actually works11:57 – How long can/should you keep testing?15:31 – Which cancers benefit most right now (colon, lung, breast, bladder)20:37 – Does this work for prostate cancer?23:05 – Inside the Personalis NeXT Personal test28:29 – False negative rates and long-term monitoring33:28 – Dr. Tan's role at Tempus AI37:22 – What does the "AI" in Tempus actually mean?40:31 – Will scans eventually be replaced?42:43 – Are patients asking about this yet?👨‍⚕️ ABOUT THE GUEST:Dr. Alan Tan is a nationally recognized GU oncology expert with extensive experience in clinical trial design, biomarker development, immunotherapy combinations, and translational research.🎙️ Subscribe to the #DoctorPodcasts Show for more expert interviews breaking down complex medical topics in plain language.👍 Like, comment, and share if you learned something new — and let us know if you'd ask your own oncologist about MRD testing after watching!⚠️ DISCLAIMER: This content is for educational purposes only and is not a substitute for professional medical advice. Always consult your physician regarding any medical condition or treatment.#MRD #ctDNA #CancerRecurrence #CancerResearch #OncologyNews #LiquidBiopsy #PrecisionOncology #KidneyCancer #BladderCancer #ProstateCancer #TempusAI #CancerAwareness #EarlyDetection #MedicalPodcast #CancerSurvivor #GUCancer #ImmunotherapyResearch #PersonalizedMedicine #OncologyResearch

A pediatric hematologist breaks down everything parents, patients, and caregivers need to know about hemophilia — from early warning signs in infants to the newest FDA-approved treatment that's changing daily life for kids as young as 6.Dr. Guy Young, Director of the Hemostasis and Thrombosis Program at Children's Hospital Los Angeles and Professor of Pediatrics at USC's Keck School of Medicine, joins Dr. Robert Cykiert, Creator and Host of the #DoctorPodcasts Show, to explain hemophilia A and B, how it's diagnosed, why 30% of cases have no family history, and how a groundbreaking new subcutaneous pen treatment is replacing painful IV infusions for kids and adults alike.🔑 TOPICS COVERED:00:00 – Why bleeding often starts as babies begin to walk01:03 – Welcome to Episode 15502:52 – What is hemophilia? Factor 8 vs. Factor 904:11 – Is hemophilia genetic? The X-linked inheritance explained05:40 – Do women get hemophilia too?07:28 – How common is hemophilia in the U.S.?08:14 – Severe vs. moderate vs. mild hemophilia10:50 – How is hemophilia diagnosed? (Simple blood tests)13:30 – The history of hemophilia treatment, from 1840 to today18:26 – How the new drug works differently from traditional Factor 8 and 9 therapy20:04 – Does it increase blood clot risk?22:11 – FDA approval history and the new expanded age range (6+)24:39 – Weekly pen injections vs. IV infusions27:43 – Gene therapy for hemophilia: where things stand33:16 – Can AI speed up new hemophilia drug development?👨‍⚕️ ABOUT THE GUEST:Guy Young, M.D. is a nationally recognized expert in pediatric hemophilia and bleeding disorders, and a leading clinical researcher on new hemophilia therapies.🎙️ Subscribe to the DoctorPodcasts Show for more expert interviews breaking down complex medical topics in plain language.👍 Like, comment, and share if you learned something new!⚠️ DISCLAIMER: This content is for educational purposes only and is not a substitute for professional medical advice. Always consult your physician regarding any medical condition or treatment.#Hemophilia #BleedingDisorder #PediatricHealth #RareDisease #HemophiliaA #HemophiliaB #FactorVIII #FactorIX #GeneTherapy #MedicalEducation #ChildrensHospital #DrPodcast #HematologyOncology #ParentingTips #RareDiseaseAwareness #FDAApproval #BloodDisorder #PediatricMedicine #HealthEducation

New hope for ovarian cancer patients! In this in-depth interview, leading gynecologic oncologist Dr. Alexander Olawaiye discusses the devastating "silent killer" — ovarian cancer — and the recent FDA approval of Lifyorli (relacorilant), a groundbreaking new drug for platinum-resistant cases. In this #DoctorPodcasts episode # 154, Dr. Olawaiye, a key investigator in the pivotal ROSella Phase 3 trial, explains the biology of the disease, why early detection is so difficult, standard treatments, and how Lifurley + nab-paclitaxel significantly improves progression-free and overall survival. Key Topics Covered: Why ovarian cancer is often diagnosed late (Stage 3–4)Symptoms, diagnosis challenges, and current limitations in screening.Platinum-resistant ovarian cancer explained.How Lifyorli works (cortisol receptor mechanism).ROSella trial results: survival benefits and safety profile.Future of antibody-drug conjugates and AI in gynecologic oncology.Importance of clinical trial participation.Watch this DoctorPodcasts Episode 154 with host, Dr. Robert Cykiert.Guest:Dr. Alexander Olawaiye, MDProfessor of Gynecologic Oncology, University of Pittsburgh / Magee-Women’s HospitalKey Investigator, ROSella Trial Timestamps:0:00 Intro & Welcome2:14 What is ovarian cancer? Why the "silent killer"?3:56 Symptoms and late-stage diagnosis6:16 How ovarian cancer is diagnosed (CA-125, imaging, etc.)8:04 Why current screening (CA-125, ultrasound, MRI) doesn't work13:28 Prognosis and platinum-based chemotherapy15:29 Platinum-resistant ovarian cancer explained18:35 Lifurley (relacorilant) + nab-paclitaxel: New FDA-approved treatment21:04 Mechanism of action and how it overcomes resistance23:55 ROSella Phase 3 Trial results – survival data30:52 Side effects and tolerability32:33 Future developments (antibody-drug conjugates, more trials)37:09 Importance of research & clinical trials41:45 Final thoughts and hope for patientsIf you or a loved one has been affected by ovarian cancer, this episode offers critical, up-to-date information from a top expert. Subscribe for more physician-led discussions on breakthrough treatments, cancer care, and women's health. Like, comment, and share to help others find this information! #OvarianCancer #Lifurley #CancerTreatment #ROSellaTrial #GynecologicOncology #WomensHealth #NewCancerDrug #PlatinumResistant #HarvardTrained #ClinicalTrials

Is your grocery list silently destroying your brain? 🧠 A groundbreaking new Harvard T.H. Chan School of Public Health study published in the American Journal of Public Health reveals that eating ultra-processed foods (UPFs) like packaged snacks, sodas, and deli meats can skyrocket your risk of developing dementia by a staggering 58%! 🚨 In this episode, nutrition expert Dr. Cindy Leung exposes the corporate greed, aggressive marketing tactics, and addictive formulations that mirror the dark history of Big Tobacco. As the U.S. government rolls out sweeping updates under the "Make America Healthy Again" guidelines to target food dyes, toxic additives, and ultra-processed ingredients, we dive deep into the biological mechanics—from gut microbiome inflammation to severe glucose spikes—that are driving this national health emergency. If you are ready to uncover the truth about what is really on your plate and take control of your long-term cognitive health, hit that SUBSCRIBE button, smash the LIKE button, and drop a comment below sharing the one food you are throwing out today! 👇00:00 - Big Tobacco Tactics & The Addictive Food Loop Addictive ultra-processed foods, hyper-palatable junk food, food company marketing strategies, tobacco industry food secrets.01:15 - Introducing Dr. Cindy Leang & The Harvard Study Harvard nutrition expert, American Journal of Public Health study, Harvard T.H. Chan epidemiology, diet and cognitive decline.03:26 - The Persistence of Food Insecurity & The Economy Food bank trends, SNAP food assistance, poverty and poor diet, living wage and grocery budgets.07:20 - Defining NOVA Classification 1 vs. NOVA 4NOVA food processing categories, minimally processed foods examples, factory-made foods vs. kitchen cooking.09:08 - The Biology of Junk Food Addiction & Cravings Dopamine release from sugar, food addiction criteria, plastic packaged shelf-stable snacks.12:23 - The Big Numbers: 58% Higher Dementia Risk Mild cognitive impairment statistics, 58 percent higher dementia risk, Health and Retirement Study Michigan, whole foods risk reduction.15:52 - Biological Mechanisms: Gut Microbiome & Glucose Spikes Insulin resistance brain damage, gut-brain axis inflammation, high blood sugar blood vessels, type 2 diabetes dementia risk.20:23 - Corporate Profit Margins & Serving Size Tricks CPG industry profits, child targeted food marketing, misleading nutrition labels, corporate food greed.22:35 - The Stress Matrix: Why Low-Income Families Rely on UPFs Food deserts San Francisco, mental health and food insecurity, budget-friendly cheap cereal, shelf-stable frozen dinner choices.26:22 - Government Policy: Banning Food Ads & Closing Loopholes Make America Healthy Again nutrition, Robert F. Kennedy Jr HHS, GRAS loophole FDA regulations, taxing sugary beverages, banning food TV ads.31:37 - The Impact of GLP-1 Drugs (Ozempic/Wegovy) on Food SalesGLP-1 weight loss drug impact, Ozempic changing food industry, suppressing junk food cravings.32:56 - Final Takeaway: Systemic Overhaul, Not Personal Failure Overhauling the food system, consumer advocacy nutrition policy, real food nutrition reform.#UltraProcessedFoods #DementiaRisk #HarvardStudy #MAHA #GutBrainAxis #BrainHealth

EPISODE 152:Did you know millions suffer from complicated UTIs (Urinary Tract Infections) yearly, and 13,000 die from them in the US alone due to infection spread to kidneys and blood? Discover how a groundbreaking new FDA-approved antibiotic, ZAYNICH, is changing the game against drug-resistant superbugs. In Episode 152 of #DoctorPodcasts, host Dr. Robert Cykiert sits down with Dennis Deruelle, M.D., Chief Medical Officer for Wockhardt USA @WockhardtLtd pharmaceutical company. They break down the critical differences between simple bladder infections and complicated UTIs like pyelonephritis (kidney infections) which can lead to #sepsis and death. Dr. Deruelle discusses how bacteria mutate to outsmart current drugs using biofilms, plasmids and efflux pumps, creating dangerous multi-drug resistant superbugs. It's evolution and survival of the fittest in real-time in the bacteria world. Learn about "ZAYNICH" a newly FDA-approved intravenous antibiotic engineered specifically to target certain complex bacterial mutated strains and save lives. If you find this medical breakthrough informative, please LIKE, COMMENT, and SUBSCRIBE to help us bring you more expert insights!

0:00 - Introduction to Episode 152 & Dr. Dennis Deruelle

2:02 - What is a UTI & Who is Most At Risk?

4:15 - Typical Symptoms of a Bladder Infection

4:56 - Complicated vs. Uncomplicated UTIs: The New Guidelines

6:49 - Risk Factors for Severe & Catheter-Associated UTIs 8:22 - Why Oral Antibiotics Fail in Complex Infections

11:15 - Pyelonephritis: How Bacteria Reach the Kidneys

12:35 - Systemic Symptoms & Mental Status Changes in the Elderly

14:35 - Shocking UTI Statistics: Hospitalizations & Mortality 16:10 - The Biofilm Secret Weapon: How Superbugs Protect Themselves

17:15 - Evolution in Real-Time: How Bacteria Become Drug-Resistant

22:31 - ZAYNICH: The New FDA-Approved Breakthrough Antibiotic

24:00 - Phase 3 Clinical Trial Data & Efficacy Results

27:25 - The Rise of MBL Mutations in the United States

29:19 - Which Drug-Resistant Superbugs Does ZAYNICH Target?

31:36 - How Plasmids Spread Drug Resistance Across the Body 32:25 - Safety, Side Effects, & Clinical Success Rates

34:30 - Future Clinical Trials & Compassionate Use Cases 37:32 - Outro & Final Expert Thoughts

#UTI

#AntibioticResistance

#MedicalNews

#Superbugs

#Urology

#Wockhardt

#FDAApproved

#HealthBreakthrough

#Pyelonephritis

The World Health Organization (WHO) has set an ambitious goal to eliminate viral hepatitis by 2030. But with over 250 million people living with Hepatitis B globally, why are we still falling short? In this episode, Dr. Robert Cykiert, founder, creator & host of #DoctorPodcasts, sits down with world-renowned viral hepatitis experts Dr. Tatyana Kushner, M.D. @TatyanaKushner (Weill Cornell Medicine) and Dr. Anu Osinusi, M.D., VP of Virology @GileadSciences, to break down the current state of liver disease, diagnosis, and treatment innovation. We dive deep into the silent differences between Hepatitis A, B, C, D, and E—uncovering how these viruses transmit, who is most at risk, and why Hepatitis B is so difficult to clear because it hides directly inside human DNA. Plus, we explore how Gilead Sciences is leveraging artificial intelligence (AI) to disrupt traditional drug development and collapse 15-year timelines into just a few years to find a functional cure. Video Timeline 0:00 – Introduction: The Global Burden of Viral Hepatitis 2:30 – What is Viral Hepatitis & How It Damages the Liver 4:04 – Shocking Global Statistics: Millions Affected Worldwide 4:54 – Gilead Sciences' Evolving Role in Fighting Liver Diseas 6:58 – Hepatitis A vs. B, C, D, & E: Key Differences Explained 7:14 – Modes of Transmission: Bloodborne vs. Fecal-Oral Routes 11:33 – Debunking Misconceptions: Can Saliva Transmit Hepatitis? 12:26 – Gilead's Current Research Priorities (HBV, HCV, HDV) 15:56 – The WHO 2030 Elimination Goal: Where Do We Stand? 17:27 – Screening Recommendations & Universal Pregnancy Testing20:12 – Addressing Hepatitis Delta: "The Forgotten Virus" 24:54 – Why Newborns & Immunosuppressed Patients Face Severe Risks 27:19 – Vaccine Guide: Who Needs the Hepatitis A & B Vaccines? 30:34 – Why Is Hepatitis B So Difficult to Eradicate? (DNA Integration) 33:10 – The Decline of Liver Transplants Due to Hepatitis C Cures 34:24 – The Next Frontier: Functional Cures for Hepatitis B37:41 – How Artificial Intelligence (AI) is Revolutionizing Drug Discovery40:46 – Trusted Online Resources for Patients & Families #HepatitisBCure #LiverHealth #MedicalAI #GileadSciences #PublicHealth #HepatitisAwareness

Is a new Ebola outbreak about to outpace the world? In this #DoctorPodcasts episode 151, two of the world's top epidemic responders break down the current crisis in the war-torn Democratic Republic of the Congo (DRC) and Uganda in Africa.Host Dr. Robert Cykiert, M.D. sits down with "Ebola Czar" Dr. Tolbert Nyenswah (Director of Public Health Emergency Management at Africa CDC) and frontline expert Dr. Daniel Bausch to discuss the Bundibugyo Ebola virus species. Discover why this rare strain currently lacks an effective vaccine, how active armed conflict is stalling contact tracing, and what the global community must do to stop a regional crisis from turning into a global threat. If you want to stay informed on global health security, please LIKE this video, SUBSCRIBE to the channel, and hit the NOTIFICATION BELL! Thanks.(Timestamps)0:00 - Introduction & US CDC Collaboration (p. 1)0:52 - Meet the Top Ebola Experts: Dr. Nyenswah & Dr. Bausch (pp. 1, 3)4:10 - Dr. Nyenswah’s Journey to Becoming the "Ebola Czar" (pp. 2-3)5:36 - Managing the Devastating 2014 West Africa Epidemic (pp. 2, 4)6:38 - How the Current DRC Outbreak Compares to 2014 (p. 5)8:45 - Frontline Realities: 50 Patients, 2 Doctors, No Vaccines (pp. 5-6, 8)12:07 - Busting Myths: How Ebola Actually Transmits (pp. 8-9)14:09 - Where the Current Epidemic Started & Major Cost Drivers (pp. 9-10)16:04 - The Critical Role (and Failure) of Contact Tracing (pp. 10-11)18:07 - Death Tolls: 2014 vs. Present Trajectory (p. 12)20:48 - The Bundibugyo Strain: Why There is No Vaccine (pp. 13-14)24:02 - Clinical Symptoms & The Power of Supportive Care (pp. 15-16)27:16 - Culture vs. Virus: Safe and Dignified Burial Practices (pp. 17, 20)33:54 - Africa CDC & WHO: A Unified Continental Plan (pp. 21-22)36:23 - Playing Catch-Up: Is the Outbreak Outpacing Us? (p. 23)40:08 - The Kenya Quarantine Center Controversy (pp. 25-26)46:10 - Civil Unrest & Broken Public Health Systems (pp. 29-30)49:43 - Can We Control It? A Call for Boots on the Ground (pp. 31-32) #EbolaOutbreak #GlobalHealth #MedicalPodcast #robertcykiertmd